stoxline Quote Chart Rank Option Currency Glossary
  
Gemini Therapeutics, Inc. (GMTX)
1.35  0 (0%)    12-30 00:00
Open: 1.36
High: 1.41
Volume: 60,423
  
Pre. Close: 1.35
Low: 1.35
Market Cap: 25(M)
Technical analysis
2023-03-03 4:49:50 PM
Short term     
Mid term     
Targets 6-month :  29.49 1-year :  34.44
Resists First :  25.25 Second :  29.49
Pivot price 23.31
Supports First :  20.93 Second :  18.26
MAs MA(5) :  23.99 MA(20) :  23
MA(100) :  18.15 MA(250) :  16.14
MACD MACD :  1.3 Signal :  1.4
%K %D K(14,3) :  73.3 D(3) :  75.2
RSI RSI(14): 60.8
52-week High :  25.25 Low :  1.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GMTX ] has closed below upper band by 38.1%. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 24.65 - 24.75 24.75 - 24.85
Low: 23.03 - 23.14 23.14 - 23.24
Close: 23.76 - 23.93 23.93 - 24.09
Company Description

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 25 Mar 2024
Gemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $60.96 - MarketBeat

Tue, 19 Mar 2024
Gemini Therapeutics (NASDAQ:GMTX) Hits New 12-Month High at $67.76 - MarketBeat

Fri, 21 Jul 2023
Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation - AccessWire

Wed, 10 Aug 2022
Gemini Therapeutics Announces Reverse Merger Pact With Hematology-Focused Company - Yahoo Finance

Wed, 10 Aug 2022
WilmerHale Represents Gemini Therapeutics in Merger with Disc Medicine - WilmerHale

Wed, 12 May 2021
Is Gemini Therapeutics Inc (GMTX) Stock Worth a Buy Wednesday? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 43 (M)
Shares Float 11 (M)
Held by Insiders 0.2 (%)
Held by Institutions 87.5 (%)
Shares Short 1,470 (K)
Shares Short P.Month 1,510 (K)
Stock Financials
EPS -1.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.41
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -19.5 %
Return on Equity (ttm) -35.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -43 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -15.18
PEG Ratio 0
Price to Book value 9.92
Price to Sales 0
Price to Cash Flow -24.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android